[b]NBS >> SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An Innovating Space[/b]
October 7, 2012
by: Henry Kawabe
| about: NBS, includes: BAX, CUR, OSIR, STEM
Disclosure: I am long NBS. (More...)
There is one change in the medical arena that investors are going to have to embrace, or at least accept: cell
therapy. In 2012, some of the best performing stocks in biotechnology have been in cell therapy. Already, we have
crossed a number of barriers. We've seen the first approved product with a cell therapy as a main component: Osiris
Therapeutics' (OSIR) Prochymal. Shares of Neuralstem (CUR) have nearly doubled in the last month alone as its
cell therapy showed a benefit of motor function in paralysis, a benefit never before reached. StemCells (STEM) has
also been a big-time performer following data that its cell therapy restored memory and enhanced synaptic function in
Alzheimer's disease. And if that's not enough, Baxter (BAX) recently reached endpoints never before conquered,
increasing exercise capacity and reducing angina due to chronic myocardial ischemia. The takeaway: It has been an
incredible year, and with such breakthrough data, it is only getting better.
In biotechnology, we've seen a number of novel therapeutics with crucial data as we inch closer to curing and
effectively treating life-threatening diseases. Cell therapy has been at the forefront of this movement - it has provided
proof of concept curing some of today's most deadly degenerative diseases - but is still in its early stages of
development.
With only one approved product that has a cell therapy as its main component, the potential for new treatments and
the outlook for those treatments is at an all-time high. The valuation for companies in this space is particularly
attractive, perhaps greater than in any other industry within biotechnology. The reason for attractive valuations is due
to skepticism among some who have yet to embrace the benefits of cell therapy. These people may believe that we'll
never see a large diversified product line of cell therapies, or that regulators will never accept the benefits of cell
therapy. However, this argument doesn't make sense, because countries around the globe are spending more on cell
therapies than at any point in our history. There is a significant cost benefit to cell therapies, not to mention
efficiency, that will replace inefficient therapeutics that are being used to treat degenerative diseases. For this reason,
we will see approvals in the cell therapy arena. We will see cheaper and more efficient therapies to treat diseases
that have limited or no current treatments, and this will occur because of clinical results, and over a period of several
years.
So how should investors play the growth of this space? Investors could invest in a company such as CUR or STEM.
But these companies are still early in the clinical process, and are more likely to benefit from the approvals of other
cell therapies; they will trade with far less upside than later-stage companies with similar valuations. You could invest
in the first approved cell therapy and OSIR. However, its product Prochymal is more of a "door opener" and not a
large revenue-producing product. The difficult aspect to finding a good investment is that there are a lot of cell therapy
companies with a lack of diversification-or only one significant product of growth-and we must assume that, despite
their promise, it may take a few years for cell therapies to gain full acceptance and reach full potential. So after
searching throughout the entire space, and reading 100s of reviews, business plans, and assessing market potential,
I feel confident that the best play in the space is NeoStem Inc. (NBS).
NeoStem
NeoStem is a $105 million market capitalization company with expertise and a presence that stretches far beyond
the norm of cell therapy and developmental-stage companies. The company operates in several segments, with a
diversified presence in the space, and has been a great investment in 2012, with an 81% return over the last six
months. The stock has returned a gain of more than 10% over the last month, but is now trading very close to its
support, therefore indicating short-term upside. Unlike most biotechnology companies of its size, NeoStem has
NBS SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An
Top 10 Most Recent News Articles
Foresight Solar Insurance Trial Beats Fixed PPA Route
Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...
Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact
A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...
Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight
Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...
Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift
A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...
Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display
A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...
Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027
A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...
Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work
Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....
Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus
A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...
Continue Reading
Boston Scientific Loads Debt Cannon for Penumbra Deal
A Very Large Financing Cart Rolled Out Boston Scientific just put an enormous stack of paper into the market, and nobody should mistake this for routine housekeeping. The company priced $3.0 billion of U.S. dollar senior notes and €4.25 billion of euro notes, with proceeds earmarked chiefly for the cash portion of its proposed Penumbra acquisition, alongside cash on...
Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus
A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....
Continue ReadingTop 5 Most Recently Viewed Articles
Understanding Recent Options Trades in Goldman Sachs Group (GS)
Bearish Sentiments in Goldman Sachs Group Options Recent activity in the financial market has brought to light the bearish stance among significant investors regarding Goldman Sachs Group (NYSE: GS). While it’s important for retail traders to stay informed, this trend signifies that something noteworthy may be unfolding within the company. Insights from Options...
Continue Reading
Calamos Investments Launches Innovative Bitcoin ETFs with Protection
Calamos Investments Introduces Unique Bitcoin ETFs Offering Significant Protection Calamos Investments has recently made headlines with the launch of two groundbreaking exchange-traded funds (ETFs), designed to provide investors with innovative exposure to Bitcoin while maintaining notable downside protection. These new ETFs, namely the CBXJ and CBTJ, offer 90% and 80%...
Continue Reading
Mawson Infrastructure Group Reports Impressive Q3 Financial Gains
Mawson Infrastructure Group's Notable Q3 Performance Mawson Infrastructure Group Inc. (NASDAQ: MIGI) is a technology company focused on establishing and managing advanced digital infrastructure platforms. The company recently revealed its financial and operational results, marking the conclusion of the third quarter and the year-to-date for 2025. Financial Highlights from...
Continue Reading
Nékter Juice Bar Teams Up with Krista Horton for New Smoothie
Nékter Juice Bar Launches Exciting Smoothie Collaboration The Krista Kolada Combines Clean Ingredients with Social Power Nékter Juice Bar, a leading name in providing fresh and healthy juice options, has recently rolled out a delightful new offering for its fans. The introduction of the Krista Kolada smoothie marks an exciting collaboration with lifestyle and parenting...
Continue Reading
Kintara Therapeutics Sets Record Date for Exciting CVR Issuance
Kintara Therapeutics Announces Record Date for CVR Issuance Kintara Therapeutics, Inc. (NASDAQ: KTRA), a biopharmaceutical company dedicated to developing innovative therapies for solid tumors, recently revealed a record date for the issuance of Contingent Value Rights (CVRs). These rights will be granted to stockholders of Kintara as part of its forthcoming merger with...
Continue Reading